SK Bioscience to export $51 bn flu vaccine to Thailand

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, announced on Monday that it has signed a deal with Thailand's state-owned Government Pharmaceutical Organization (GPO) to supply the cell-cultured influenza vaccine "Sky Cell Flu" bulk amounting to 68 billion won ($50.7 million).

Following a memorandum of understanding (MOU) signed with GPO last month for local vaccine production and development infrastructure, SK Bioscience has now entered into an agreement to transfer the production technology of Sky Cell Flu.

As a result, the Korean company explained that it will supply the cell-cultured influenza vaccine bulk to GPO through the Thai company BGT.

SK Bioscience plans to collaborate with GPO in the medium to long term, promoting vaccine localization in Thailand and the ASEAN region, and building infrastructure to respond to new pandemics.

Write to Hyun-Ah Oh at 5hyun@hankyung.com